Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nkarta Inc (NKTX)

Nkarta Inc (NKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 115,662
  • Shares Outstanding, K 70,958
  • Annual Sales, $ 0 K
  • Annual Income, $ -108,790 K
  • EBIT $ -128 M
  • EBITDA $ -126 M
  • 60-Month Beta 0.83
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.36

Options Overview Details

View History
  • Implied Volatility 127.73% ( +12.60%)
  • Historical Volatility 135.30%
  • IV Percentile 62%
  • IV Rank 14.64%
  • IV High 636.43% on 01/06/25
  • IV Low 40.45% on 06/11/24
  • Put/Call Vol Ratio 0.15
  • Today's Volume 172
  • Volume Avg (30-Day) 253
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 4,961
  • Open Int (30-Day) 4,816

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.45
  • Number of Estimates 6
  • High Estimate -0.39
  • Low Estimate -0.49
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +22.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.31 +61.07%
on 03/26/25
2.34 -9.83%
on 03/27/25
+0.68 (+47.55%)
since 03/25/25
3-Month
1.31 +61.07%
on 03/26/25
2.58 -18.22%
on 01/27/25
-0.38 (-15.26%)
since 01/24/25
52-Week
1.31 +61.07%
on 03/26/25
8.33 -74.67%
on 05/03/24
-4.71 (-69.06%)
since 04/25/24

Most Recent Stories

More News
Nkarta to Participate in an April Investor Conference

NKTX : 2.11 (-4.09%)
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

NKTX : 2.11 (-4.09%)
Nkarta to Participate in March Investor Conferences

NKTX : 2.11 (-4.09%)
Nkarta, Inc. Opens Enrollment for Ntrust-2 Trial Evaluating NKX019 in Multiple Autoimmune Diseases

Nkarta opens Ntrust-2 trial for NKX019 in systemic sclerosis, myositis, and vasculitis; myasthenia gravis trial also initiated.Quiver AI SummaryNkarta, Inc. has announced the opening of patient enrollment...

NKTX : 2.11 (-4.09%)
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

NKTX : 2.11 (-4.09%)
Nkarta to Participate in an Upcoming Investor Conference

NKTX : 2.11 (-4.09%)
Nkarta to Participate in an Upcoming Investor Conference

NKTX : 2.11 (-4.09%)
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

NKTX : 2.11 (-4.09%)
Why Nkarta Stock Is Soaring Today

One analyst is now more bullish about this clinical-stage biotech stock.

NKTX : 2.11 (-4.09%)
RJF : 137.37 (+0.08%)
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END

ONCY : 0.5562 (-4.65%)
NKTX : 2.11 (-4.09%)
AMAM : 28.00 (+0.07%)
ELEV : 0.3759 (+1.05%)
ONC.TO : 0.77 (-4.94%)
AMGN : 280.84 (+0.36%)

Business Summary

Nkarta Inc. is a biopharmaceutical company. It develops and commercializes cell therapies for cancer treatment. The company's product candidate includes NKX101 and NKX019, which are in clinical stage. Nkarta Inc. is based in South San Francisco, California.

See More

Key Turning Points

3rd Resistance Point 2.26
2nd Resistance Point 2.21
1st Resistance Point 2.16
Last Price 2.11
1st Support Level 2.05
2nd Support Level 2.00
3rd Support Level 1.95

See More

52-Week High 8.33
Fibonacci 61.8% 5.65
Fibonacci 50% 4.82
Fibonacci 38.2% 3.99
Last Price 2.11
52-Week Low 1.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar